JOHN HOPE FRANKLIN CENTER

Invivyd's CANOPY Phase 3 trial demonstrated that PEMGARDA (pemivibart) achieved an 84% relative risk reduction in symptomatic COVID-19 compared to placebo over six months (nominal p <0.0001).

Duke University researchers demonstrated that combining enzalutamide with standard hormonal therapy extends survival by 30% in men with metastatic prostate cancer.

Duke University researchers have developed SBI-810, an experimental non-opioid painkiller that targets specific receptors in the brain and spinal cord to provide pain relief without the addictive properties of opioids.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

ImmVira presented Phase I clinical results for MVR-C5252, an oncolytic herpes simplex virus therapy targeting malignant glioma, at the 2025 AACR annual meeting.

Researchers at UT Health San Antonio have developed "chemical endocytic medicinal chemistry," a novel approach that could enable large-molecule drugs to be taken orally rather than intravenously.

4basebio has received Good Manufacturing Practice certification from the UK's Medicines and Healthcare products Regulatory Agency, enabling the supply of synthetic DNA for clinical applications in cell and gene therapies.

Duke University researchers have created a breakthrough hydrogel-based cartilage replacement that demonstrates 26% greater tensile strength and 66% higher compression resistance than natural knee cartilage.

The American Cancer Society (ACS) has committed $517 million to research grants, with a significant focus on supporting early-career investigators and promoting diversity in cancer research.

A novel patient navigation intervention (NDURE) doubled the rate of timely post-operative radiation therapy initiation in head and neck cancer patients, showing a 35% improvement over usual care.